Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma
Purpose
Vitreoretinal lymphoma (VRL) is a rare disease of B-cell origin with poor prognosis. Regulatory cytokines promote tumor development by suppressing antitumor immunity in several cancer types. To identify the regulatory cytokines associated with poor prognosis in patients with B-cell VRL, we determined the regulatory cytokines profiles in the vitreous humor of patients with VRL.
Methods
This retrospective study included 22 patients with VRL, 24 with noninfectious uveitis (NIU), and 20 with idiopathic epiretinal membrane (control). Undiluted vitreous fluid was obtained at the beginning of diagnostic vitrectomy at the Kyushu University Hospital, in Fukuoka, Japan, from January 2008 to April 2016. Vitreous concentrations of regulatory cytokines were assessed using a cytometric beads assay and association with clinical data was examined.
Results
The mean observation period was 48.7 months during the survey period from January 2008 to December 2019 in patients with VRL. Vitreous levels of interleukin (IL)-10 and IL-22 were increased in patients with VRL compared to those in the patients with NIU and the control. IL-35 and soluble IL-2 receptor α levels were significantly higher in patients with VRL and NIU than those in the control group. The five-year overall survival rates for the group with high intravitreal IL-35 was significantly poorer than those for the group with low intravitreal IL-35, who were diagnosed with VRL at the onset (P < 0.05).
Conclusion
Our results suggest that high intravitreal IL-35 levels indicate poor prognosis for patients diagnosed with B-cell VRL at the onset.
Conflict of interest
No
Authors 1
Last name
TAKEDA
Initials of first name(s)
AT
Department
Ophthalmology, Kyushu University
City
Fukuoka
Country
Japan
Authors 2
Last name
Koh-Hei Sonoda
Initials of first name(s)
KH.S
Department
Ophthalmology, Kyushu University
City
Fukuoka
Country
Japan
This website uses cookies to ensure you get the best experience on our website.
Learn more